Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice

This article was originally published in PharmAsia News

Executive Summary

In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.

You may also be interested in...

Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication

FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.

Colcrys Promo Eats Pavement As FDA Objects To Ad Of Motorcyclist Holding Teacup

FDA asks Mutual to stop using a pharmacy sell sheet that describes the gout drug as “gentle.” It also cites a video for failing to convey serious risk information and suggesting the drug is as tolerable as a placebo and superior to NSAIDs.

Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks

The agency will also ask its Arthritis Advisory Committee at a June 21 meeting whether the sponsor should explore lower doses for the interleukin-1 beta inhibitor.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts